BIOCRYST PHARM (BO1 BE) stock market data APIs
€6.0073
0(0%)
as of December 18, 2025
Try our APIs with
free plan!
BIOCRYST PHARM Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for BO1.BE.
Prev. Close
6.0073
Open
6.0073
High
6.0073
Low
6.0073
52 wk Range
5.536-9.896
Market Cap
1 856 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BIOCRYST PHARM data using free add-ons & libraries
Get BIOCRYST PHARM Fundamental Data
BIOCRYST PHARM Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BIOCRYST PHARM News
New
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025?
Wondering if BioCryst Pharmaceuticals at around $7.59 is quietly setting up a value opportunity, or just another volatile biotech swing? Let us unpack what the market is really pricing in here. The st...
Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ Stocks
After a blistering run, the stock market has lately found itself stuck in a bit of a trading rut, with more and more chatter that the AI boom is drifting from ‘transformational’ toward ‘show-me-...
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
BioCryst Pharmaceuticals, Inc. –ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older– -Oral pellet formulation provides child-friendly method o...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCrys...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
